Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18420877 | 0.85 | KDM4E (0.35) | CDK8FGFR1JAK2NTRK1RET | |
| SCHEMBL15010142 | 0.85 | KDM4E (0.35) | CDK8FGFR1JAK2NTRK1RET | |
| SCHEMBL10631684 | 0.85 | MAPT (0.40) | FGFR1RETKDM4EL3MBTL1FERMT2 | |
| SCHEMBL25208777 | 0.85 | FGFR1 (0.36) | FGFR1RETACVR1KDM4EL3MBTL1 | |
| SCHEMBL16858593 | 0.81 | EGLN2 (0.39) | — | |
| SCHEMBL24008901 | 0.81 | RET (0.44) | FGFR1RETPDGFRAPDGFRBFLT1 | |
| SCHEMBL30430404 | 0.81 | RET (0.44) | FGFR1RETPDGFRAPDGFRBFLT1 | |
| SCHEMBL14128913 | 0.80 | PDGFRB (0.38) | FGFR1KDM4EPDGFRAPDGFRBTLR8 | |
| SCHEMBL591523 | 0.78 | CDK8 (0.49) | CDK8ACVR1KDM4EFERMT2CCNC | |
| SCHEMBL29933815 | 0.78 | FERMT2 (0.49) | CDK8ACVR1KDM4EFERMT2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2720545-B1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140128367-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128367-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120329743-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329743-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| WO-2012174176-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-2346830-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-7863266-B2 | Therapeutic pyrazoloquinoline urea derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329743-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | NR1H2, HRH2, HRH1 | CDK8 2357/4885FGFR1 638/4885JAK2 660/4885 |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | CDK8 3171/4885FGFR1 3575/4885JAK2 2054/4885 |
| US-20140128367-A1 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS | NR1H2, HRH2, HRH1 | CDK8 2232/4885FGFR1 723/4885JAK2 940/4885 |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | CDK8 1694/4885FGFR1 927/4885JAK2 1108/4885 |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE10A, PDE4A | CDK8 1927/4885FGFR1 3032/4885JAK2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.